Detection of arginine methylation of EGFR for prediction of resistance to therapy
AssigneeBoard of Regents, The University of Texas System
InventorsMien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
Life of this patent
Estimating the term…
Abstract
This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
Claims8
A method of treating a patient having cancer comprising administering an effective amount of cetuximab to a patient in need thereof, said patient having been determined to have a cancer cell comprising (i) unmethylated Arg at position 198 and/or (ii) unmethylated Arg at position 200 of a EGFR protein expressed in the cancer cell.
Dependencies are inferred from the claim text.